Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Contributing Authors: P Barrett-Lee A Casbard J Abraham K Hood R Coleman P Simmonds H Timmins D Wheatley R Grieve G Griffiths N Murray

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

1404 patients with bone metastases from breast cancer were randomized to receive treatment with either oral ibandronic acid or intravenous zoledronic acid. The frequency and timing of skeletal-related events (SREs) was the primary non-inferiority endpoint. After 96 weeks of treatment, 50 mg of oral ibandronic acid given daily was inferior to 4 mg of intravenous zoledronic acid given every 4 weeks ...